254 related articles for article (PubMed ID: 17984134)
1. Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?
von Haehling S; Lainscak M; Anker SD
Eur Heart J; 2007 Dec; 28(23):2830-1. PubMed ID: 17984134
[No Abstract] [Full Text] [Related]
2. Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial.
Van Gaal LF; Caterson ID; Coutinho W; Finer N; Maggioni AP; Sharma AM; Torp-Pedersen C; Ge H; Moran SA; Shepherd GM; James WP;
Diabetes Obes Metab; 2010 Jan; 12(1):26-34. PubMed ID: 19758358
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial.
Torp-Pedersen C; Caterson I; Coutinho W; Finer N; Van Gaal L; Maggioni A; Sharma A; Brisco W; Deaton R; Shepherd G; James P;
Eur Heart J; 2007 Dec; 28(23):2915-23. PubMed ID: 17595194
[TBL] [Abstract][Full Text] [Related]
4. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of the month. After the storm over central anorectic agents, the "STORM" study of sibutramine].
Scheen AJ
Rev Med Liege; 2001 Jan; 56(1):56-8. PubMed ID: 11256141
[TBL] [Abstract][Full Text] [Related]
6. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
[TBL] [Abstract][Full Text] [Related]
7. Orlistat and sibutramine beyond weight loss.
Mannucci E; Dicembrini I; Rotella F; Rotella CM
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
[TBL] [Abstract][Full Text] [Related]
8. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
Caterson ID; Finer N; Coutinho W; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Legler UF; Shepherd GM; Rode RA; Perdok RJ; Renz CL; James WP;
Diabetes Obes Metab; 2012 Jun; 14(6):523-30. PubMed ID: 22192338
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
Maggioni AP; Caterson I; Coutinho W; Finer N; Gaal LV; Sharma AM; Torp-Pedersen C; Bacher P; Shepherd G; Sun R; James P;
J Cardiovasc Pharmacol; 2008 Nov; 52(5):393-402. PubMed ID: 19033818
[TBL] [Abstract][Full Text] [Related]
10. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials.
Kim SH; Lee YM; Jee SH; Nam CM
Obes Res; 2003 Sep; 11(9):1116-23. PubMed ID: 12972682
[TBL] [Abstract][Full Text] [Related]
11. The obese older female patient: CV risk and the SCOUT study.
Coutinho WF
Int J Obes (Lond); 2007 Nov; 31 Suppl 2():S26-30; discussion S31-2. PubMed ID: 17968434
[TBL] [Abstract][Full Text] [Related]
12. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O
Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258
[TBL] [Abstract][Full Text] [Related]
13. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
Andersson C; Weeke P; Fosbøl EL; Brendorp B; Køber L; Coutinho W; Sharma AM; Van Gaal L; Finer N; James WP; Caterson ID; Rode RA; Torp-Pedersen C; ;
Metabolism; 2009 Aug; 58(8):1109-15. PubMed ID: 19454355
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacotherapy for weight loss in patients with type 2 diabetes].
Toubro S
Ugeskr Laeger; 2007 Aug; 169(33):2619-22. PubMed ID: 17725907
[No Abstract] [Full Text] [Related]
15. The effect of sibutramine therapy on occurrence of depression symptoms among obese patients.
Slovacek L; Pavlik V; Slovackova B
Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):e43-4. PubMed ID: 18676135
[No Abstract] [Full Text] [Related]
16. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
Daniels SR; Long B; Crow S; Styne D; Sothern M; Vargas-Rodriguez I; Harris L; Walch J; Jasinsky O; Cwik K; Hewkin A; Blakesley V;
Pediatrics; 2007 Jul; 120(1):e147-57. PubMed ID: 17576783
[TBL] [Abstract][Full Text] [Related]
17. Weight loss and health-related quality of life.
Fontaine KR
Am J Manag Care; 2001 Sep; 7(9):926-7. PubMed ID: 11570025
[No Abstract] [Full Text] [Related]
18. Does sibutramine keep the weight off?
Maughan KL
J Fam Pract; 1999 Jun; 48(6):420. PubMed ID: 10386483
[No Abstract] [Full Text] [Related]
19. Effect of sibutramine and of cognitive-behavioural weight loss therapy in obesity and subclinical binge eating disorder.
Bauer C; Fischer A; Keller U
Diabetes Obes Metab; 2006 May; 8(3):289-95. PubMed ID: 16634988
[TBL] [Abstract][Full Text] [Related]
20. [Weight reduction. Antiobesity drug treatment in type-2 diabetics].
Verspohl EJ
Pharm Unserer Zeit; 2002; 31(3):300-7. PubMed ID: 12071127
[No Abstract] [Full Text] [Related]
[Next] [New Search]
